Navigation Links
Arrien Pharmaceuticals Appoints Dr. Philip LoGrasso to its Scientific Advisory Board for CNS/Neurodegenerative Diseases

ANSONIA, Conn., Oct. 20, 2011 /PRNewswire/ -- Arrien Pharmaceuticals is an early stage Drug Discovery company located in the Connecticut & Salt Lake City area announces today the appointment of Philip LoGrasso, Ph.D., to its Scientific Advisory Board. Dr. LoGrasso will work with the Arrien Pharmaceuticals team to facilitate the development of its CNS/Neurodegenerative pipeline portfolio.

"It is a great opportunity to participate in developing Arrien's promising small molecule therapeutics pipeline," said Dr. LoGrasso. "I look forward to assisting in the development of Arrien's innovative therapeutics pipeline for Parkinson's, Alzheimer's and other CNS diseases as a member of the Scientific Advisory Board."

"Dr. LoGrasso's enormous experience in developing novel therapeutics in to the clinic, as well as his strong research interests in molecular neuroscience, will be a valuable scientific addition to Arrien," stated Hariprasad, Ph.D., and Rajendra P. Appalaneni Chief Executive Officer of Arrien Pharmaceuticals. "As a leader in the field of CNS/Neurodegenerative therapeutics, Dr. LoGrasso will contribute valuable science and expertise as we move our ORS-1006 programs forward into IND enabling studies and to the clinical development."

Dr. LoGrasso is a Professor in the Molecular Therapeutics Department and Senior Director of Drug Discovery in the Translational Research Institute within The Scripps Research Institute. Prior to joining Scripps Florida, Dr. LoGrasso was a Program Officer at the NIH and had responsibility for funding a $50MM research portfolio of grants in the areas of chemical biology, medicinal chemistry, pharmacology, and postdoctoral and graduate training fellowships.

In his most recent industrial position Dr. LoGrasso was the Director of preclinical research and development at Avera Pharmaceuticals. In this role he placed two compounds into Phase II clinical development for depression and cognitive impairment.

Dr. LoGrasso was a Research Fellow at Merck Research Laboratories for nearly nine years working in the areas of inflammation and molecular neuroscience. His main research focus was on MAP-kinase signal transduction pathways and associated mechanistic enzymology, inhibitor characterization, and structure-function relationships for MAP kinases.

Dr. LoGrasso received his B.A. in chemistry from New York University in 1985, his M.S. in biochemistry from Florida State University in 1988, and his Ph.D. in pharmacology from the University of Florida in 1992. This was followed by postdoctoral training at the Sandoz Research Institute (now Novartis) working in the area of atherosclerosis and metabolic disease focusing on enzymes in the cholesterol biosynthetic pathway.

Arrien Pharmaceuticals is working for a possible licensing & alliance deals for near term funding for Phase I, II trials and to expand significantly to its value based pipeline. Arrien is seeking collaborations with companies for a number of programs particularly ORS-1006 targeting LRRK2 mediated Parkinson's disease and other CNS indications.

About Arrien Pharmaceuticals & FFDD™

Arrien Pharmaceuticals LLC is a small molecule targeted therapeutics drug discovery and development company working towards targeting cell signaling pathways - A target class in treating Neurodegenerative/CNS, Cancer, Inflammation and Metabolic diseases. Arrien proprietary Fragment-Field Drug Design (FFDD™) Technology typically involves scaffold-based design strategy; extensively implemented by utilizing structural biology data inputs and to assist Medicinal Chemistry in early phase of lead-to-drug-lead identification process. Arrien cost-competent approach assists its technology to influence target-specific leads for multiple protein targets. Moreover, Arrien technology has proven in the identification of potent and highly selective clinical stage candidates.

For further information on Arrien Pharmaceuticals, please visit the company's website


Arrien Pharmaceuticals CEO/CSO at Tel. 203-331-3000 or 801-285-7427

SOURCE Arrien Pharmaceuticals LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arrien Pharmaceuticals Founders closes $2.0 Million Series A Financing
2. Critical Alerts For Intel, Mosaic, Deckers, Foot Locker, and Jazz Pharmaceuticals Released By Seven Summits Research
3. Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl
4. Amylin Pharmaceuticals Reports Third Quarter Financial Results
5. CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum
6. ADVENTRX Pharmaceuticals to Present at the 10th Annual BIOInvestor Forum Conference on October 26
7. Rock Creek Pharmaceuticals Announces Expanded International Shipping Options for Anatabloc™, Physician Conferences on Anatabine Research
8. Amerigen Pharmaceuticals and Stason Pharmaceuticals Enter Into Collaboration Agreement for Development of Generic Oral Oncology Products
9. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
10. JHP Pharmaceuticals Enters Agreement to Produce Diagnostic Aid
11. Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals
Post Your Comments:
(Date:12/1/2015)... 1, 2015 --> ... report "Nucleic Acid Labeling Market by Product (Reagents & ... Primer, In Vitro Transcription, Reverse Transcription, End Labeling), by ... The global market is expected to reach USD 1,925.7 ... growing at a CAGR of 8.65%. Browse ...
(Date:12/1/2015)... 1, 2015 During the recent 2015 ... San Francisco, CA , Medinol Ltd. continued ... marketplace. During a satellite symposium, "The BioNIR eDES: ... Minimize Restenosis", a renowned physician panel discussed the ... CoCr Coronary Stent System and the Medinol eDES ...
(Date:12/1/2015)... N.J. , Dec. 1, 2015 ... against HIV/AIDS, Johnson & Johnson (NYSE: JNJ ... its Janssen Pharmaceutical Companies to significantly reduce the ... who make up 74 percent of new HIV ... Announced on World AIDS Day, these new initiatives ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation claim ... of hospital and nonhospital care, according to a recent study by the Workers Compensation ... Edition , found medical payments per claim with more than seven days of lost ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... to continue the expansion of the company’s growing product line of food safety ... (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015—Since ... improvements in scientific research and discoveries, leading us to better understand the disease’s ... to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World AIDS Day” provides ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... the 7th Annual 2015 Golden Bridge Business Awards under the New Products and ... zero capex web based sample management software that helps labs organize ...
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... It’s ... has a tattoo — a number even greater among Millennials (a whopping one in ... are more and more people who are dissatisfied with their ink. In fact, ...
Breaking Medicine News(10 mins):